NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Viridian Therapeutics, Inc.\DE VRDN
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$70.8M
▲ 23359.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-49.2%
Net margin · FY25
-483.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 70.8M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 484 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-49.2%
Return on equity, FY2025
ROE
Operating margin-512.9%
Net margin-483.6%
Return on assets-41.7%
Each USD of equity lost 49 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+132.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+241.9%
+132.2%
+39.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 899.4M
total assets, end of FY2025
Total assetsUSD 899.4M
EquityUSD 722.2M
CashUSD 212.4M
Current ratio12.65×
Equity funds 80% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.4
−0.3
−0.3
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.4
−0.3
−0.3
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
·
0.0
0.0
·
Net income $B
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
−5.31
−4.05
−6.66
−31.13
−20.04
−1.10
−1.38
−28.21
−21.02
−3.50
−12.23
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−49.2
−48.5
−56.8
−44.6
−51.6
−163.1
−124.8
−72.8
·
·
·
·
·
Shares out B
0.10
0.08
0.05
0.04
0.02
0.00
0.00
0.03
0.02
0.00
0.00
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed